Home / Going-concern warnings / GENELUX Corp
Filed 2026-05-07 路 Form 10-Q 路 Accession 0001493152-26-021710 micro
Price before filing: $2.87 (2026-05-06 close, split/dividend-adjusted)
Market cap at flag: $92.0M (2026-05-07) 路 Latest: $108.8M (2026-10-16)
| Window | GNLX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +2.1% | +0.7% | +1.4% | 2026-06-08 |
| 90 days | -12.5% | +5.2% | -17.7% | 2026-08-05 |
| 180 days | pending | pending | until 2026-11-03 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 5 insiders sold $43K (6 sales)
30 days after: 5 insiders sold $43K (6 sales)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-02 | Thomas John Director | Sale | 10,000 | $2.90 | $29K | yes | Form 4 |
| 2026-03-24 | Cappello Joseph Chief Technical Officer | Sale | 906 | $2.42 | $2K | no | Form 4 |
| 2026-03-24 | Smalling Ralph Head of Regulatory | Sale | 345 | $2.42 | $835 | no | Form 4 |
| 2026-03-24 | Yu Yong SVP, Clinical Development | Sale | 906 | $2.42 | $2K | no | Form 4 |
| 2026-03-24 | Zindrick Thomas President and CEO | Sale | 3,582 | $2.42 | $9K | no | Form 4 |
| 2026-03-25 | Smalling Ralph Head of Regulatory | Sale | 240 | $2.51 | $602 | no | Form 4 |
| 2026-05-07: red flag filed | |||||||
| 2026-05-11 | Cappello Joseph Chief Technical Officer | Sale | 605 | $2.97 | $2K | no | Form 4 |
| 2026-05-11 | Smalling Ralph Head of Regulatory | Sale | 270 | $2.98 | $804 | no | Form 4 |
| 2026-05-11 | Yu Yong Chief Scientific Officer | Sale | 605 | $2.97 | $2K | no | Form 4 |
| 2026-05-11 | Zindrick Thomas President and CEO | Sale | 2,798 | $2.94 | $8K | no | Form 4 |
| 2026-06-01 | Thomas John Director | Sale | 10,000 | $2.98 | $30K | yes | Form 4 |
| 2026-06-03 | Smalling Ralph Head of Regulatory | Sale | 192 | $2.93 | $563 | no | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-02-06 to 2026-06-06. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.